Australia is eagerly awaiting the arrival of retatrutide, a innovative dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://deniszagj153208.wikijournalist.com/576373/novo_nordisk_s_retatrutide_australia_a_promising_hope_for_obesity_treatment